KR20010029185A - Antiviral agent and anticancer agent containing unsaturated fatty acid extract of sasamum indicum l. and alkaline extract of potato as active ingredients - Google Patents

Antiviral agent and anticancer agent containing unsaturated fatty acid extract of sasamum indicum l. and alkaline extract of potato as active ingredients Download PDF

Info

Publication number
KR20010029185A
KR20010029185A KR1019990041858A KR19990041858A KR20010029185A KR 20010029185 A KR20010029185 A KR 20010029185A KR 1019990041858 A KR1019990041858 A KR 1019990041858A KR 19990041858 A KR19990041858 A KR 19990041858A KR 20010029185 A KR20010029185 A KR 20010029185A
Authority
KR
South Korea
Prior art keywords
unsaturated fatty
fatty acid
extract
acid
potato
Prior art date
Application number
KR1019990041858A
Other languages
Korean (ko)
Inventor
손남율
Original Assignee
손남율
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 손남율 filed Critical 손남율
Priority to KR1019990041858A priority Critical patent/KR20010029185A/en
Publication of KR20010029185A publication Critical patent/KR20010029185A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/31Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/17Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/37Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: Provided is an antiviral agent which contains unsaturated fatty acid extract of sasamum indicum L. and alkaline extract of potato as active ingredients, shows inhibiting effects on infection of various viruses such as influenza virus and retrovirus, and on bacteria growth, as well as destroys malignant tumor without any side effect. CONSTITUTION: An antiviral agent, which comprises unsaturated fatty acid extract of sasamum indicum L. and alkaline extract of potato, as effective ingredients, is manufactured by the following steps of: washing sasamum indicum L. and drying it to lose 15% of water; heating it in a microwave followed by press extracting it to obtain unsaturated fatty acid extract thereof; washing potato and followed by press extracting it to obtain alkaline extract thereof; mixing the unsaturated fatty acid extract and the alkaline extract in a mixing ratio of 1:1. Wherein, an unsaturated fatty acid component is one of Palmiticaicd, 0.4-1.1% of Stearicaicd, 0.3-0.6% of Sesamin, 0.3-0.6% of Seamolin and Sesamol, and an alkaline component is one of 0.04mg of Vitamin B1, 0.04mg of Vitamin B2, 0.4mg of Niacin and 99mg of Vitamin C.

Description

항바이러스제 및 항암제{.}Antiviral and Anticancer Agents {.}

본 발명은 유효성분으로서 참깨(Sesamum indjcum)의 불포화지방산과 감자(potato)의 알칼리 추출물로 이루어지는 항바이러스제 및 항암제에 관한 것이다.The present invention relates to an antiviral agent and an anticancer agent comprising an unsaturated fatty acid of sesame seeds (Sesamum indjcum) and an alkali extract of potato (potato).

종래 수많은 항바이러스제 및 항암제가 알려져 왔다. 그러나 항바이러스제는 주로 박테리아에만 효과가 있는 것으로 바이러스에 대한 효과는 있다고해도 극히 약한 것이며, 더욱이 항생물질은 통상 부작용을 지니고 있어 때때로 아주 혹독하고 심각한 것으로 될 수 있었다.Numerous antiviral and anticancer agents have been known in the art. However, antiviral drugs mainly work only on bacteria and are extremely weak, even if they are effective against viruses. Moreover, antibiotics usually have side effects, which can sometimes be very harsh and severe.

인플루엔자, 간염, 암, 저혈압, 비만, 에이즈, 당뇨병 등의 바이러스에 의해 많은 질병이 발생하나 불행하게도 이들 종래의 바이러스성 질병에 대해 명확한 효능을 보이는 약물치료는 거의 없는 실정이고 특히, 아무 부작용 없이, 성인T- 당뇨병 또는 에이즈를 일으키는 레크로바이러스(Retroviruse)에 대해 충분히 효과적인 의약은 없었다.Many diseases are caused by viruses such as influenza, hepatitis, cancer, hypotension, obesity, AIDS and diabetes, but unfortunately there are few drug treatments that show clear efficacy against these conventional viral diseases. There is no medicament that is effective enough against retroviruses that cause adult T-diabetes or AIDS.

또한 일일 식이요법에서 취할 수 있었고 아무 부작용없이 예방효과를 지니는 항바이러스제에 대해서도 알려진 것이 없었다. 따라서 북작용을 지니지 않는 에이즈 및 에이즈관련 콤플렉스의 효율적인 치료에 관한 연구는 특히 어려워서 장기간의 화학요법을 통해 제한된 효과를 나타내는 몇몇 의약은 심각한 부작용을 보일 수 있다. 항암제로서 지금까지 알려진 항암제는 암세포를 파괴할 뿐만아니라 정상세포까지도 손상시킬 수 있도록 작용하였기 때문에 이들 항암제는 혹독한 부작용을 보여왔다. 또 이들 항암제는 구강투여를 사용하기가 곤란하였기 때문에 통상 정맥주사로 사용되어 왔던바, 이들 항암제에는 많은 문제가 존재하고 있었다. 그러므로 항 HIV제로서 부작용이 없고 세포상의 바이러스 흡착을 억제하는 작용, 바이러스 복제 억제작용 및 면역활성을 활당화시키는 작용을 지니는 제제를 발명해야할 필요가 있었다.There was also no known antiviral agent that could be taken in a daily diet and had a preventive effect without any side effects. Thus, studies on the effective treatment of HIV- and AIDS-related complexes that have no adverse effects are particularly difficult, and some medications that have limited effects through long-term chemotherapy may have serious side effects. Since anticancer drugs known as anticancer agents have not only destroyed cancer cells but also damaged normal cells, these anticancer drugs have had severe side effects. In addition, these anticancer agents have been commonly used for intravenous injection because of difficulty in oral administration. There have been many problems with these anticancer agents. Therefore, it was necessary to invent an agent which has no side effects as an anti-HIV agent and has an action of inhibiting viral adsorption on cells, inhibiting virus replication and activating immune activity.

따라서 본 발명의 목적은 상기 문제점을 해결하여 레트로바이러스에 대한 효능이 있고 부작용없이 악성종양(암)을 파괴하는 항암제를 제공하는 것이다.Accordingly, an object of the present invention is to provide an anticancer agent that solves the above problems and is effective against retroviruses and destroys malignant tumors (cancer) without side effects.

본 발명자는 상기 문제롤 해결하기 위해 예의 연구한 결과, 참깨(Sesamum indicum L.)와 감자(Patato)의 불포화 지방산, 알칼리 추출물이 강한 항바이러스 및 항암작용을 지니고 상기 불포화지방산 알칼리 추출물이 동물 또는 인간에 대한 극히 안전하고 부작용을 지니지 않는다는 것을 발견하여 본 발명을 개발하였다.The present inventors have studied diligently to solve the above problems, and as a result, unsaturated fatty acids and alkali extracts of sesame seeds (Sesamum indicum L.) and potato (Patato) have strong antiviral and anticancer activity, and the unsaturated fatty acid alkali extracts are used in animals or humans. The present invention was developed by discovering that it is extremely safe and has no side effects.

본 발명의 유효성분은 참깨를 정선수세하여 수분 15% 건조후 전자렌즌에 넣고 타지않게 가열하여 압착하여 불포화지방산을 추출하고 감자를 정선수세하여 비타민 C, B1, B2, 나이신, 판토탠산(B3), 칼륨(K), 인, 칼슘 등 무기질 영양소는 장시간 열을 가하면 파괴되므로 영양소를 보존하기 위하여, 전자렌즌에서 열을 가해 압착하여 추출한 다음 알칼리용액을 1:1로 혼합한다. 불포화지방산 용액의 성분은 팔미트산, 스태아르산, 올레산, 리놀레산, 항산화성분, 세사민 0.4∼1.1%, 세사몰린 0.3∼0.6%, 세사몰등을 들 수 있고 가열, 압착추출등의 공지의 추출법을 사용할 수 있다. 가열 압착추출물 이외의 추출용매로서 에탄올, 아세톤 등을 사용할 수 있다.The active ingredient of the present invention is a sesame seed is settled in moisture 15%, dried in an microwave oven, heated to compression to extract the unsaturated fatty acid and pressed potatoes, vitamin C, B1, B2, nisin, pantotanic acid (B3) Inorganic nutrients such as), potassium (K), phosphorus, and calcium are destroyed when heat is applied for a long time. In order to preserve the nutrients, the mixture is extracted by applying heat in a microwave oven and then mixed with an alkaline solution in a 1: 1 ratio. The components of the unsaturated fatty acid solution include palmitic acid, stearic acid, oleic acid, linoleic acid, antioxidants, sesamin 0.4-1.1%, sesamoline 0.3-0.6%, sesamol and the like, and known extraction methods such as heating and compression extraction. Can be used. Ethanol, acetone, or the like may be used as an extraction solvent other than the heat compression extract.

상기 추출물의 유효성분을 부형제, 결합제, 휘석재 등의 적당한 담체와 혼합할 수 있고 예를 들면 캡슐제, 연고제, 시럽, 좌약제, 주사제로서 경구용 혹은 비경구용으로 또는 혼합하여 용액, 그대로 캡슐의 형태로 단독 투여, 농축액을 이용 또는 다른 음식물에 혼합하여 사용할 수 있다.The active ingredient of the extract may be mixed with a suitable carrier such as excipients, binders, or ignitants, for example, capsules, ointments, syrups, suppositories, injections, orally or parenterally, or mixed, as a solution, as the capsule In the form of a single dose, the concentrate may be used or mixed with other foods.

투여량은 대상으로되는 질환의 종류, 정도에 따라 다르나, 액체형태일 경우는 1∼100mg 1용액을 1ml ∼ 500ml로 투여해야 한다.The dosage varies depending on the type and extent of the disease, but in the case of liquid form, 1 to 100 mg of 1 solution should be administered in 1 ml to 500 ml.

참깨 불포화지방산 추출물과 감자 알칼리 추출물을 쥐 및 생쥐에 대해 시험을 행한바 사망률은 없고 동물의 이상행동이 관측되지 않으며 혈액의 생화학시험 및 조직의 병리학 실험에 있어 값이 나타나지 않는다.Sesame unsaturated fatty acid extract and potato alkali extract were tested in rats and mice. There was no mortality, no abnormal behavior was observed, and no value was found in blood biochemical tests and tissue pathology experiments.

본 발명은 항바이러스제, 항암제, 항박테리아제로서 본 발명에 의하면 인플루엔자바이러스 및 간염바이러스 등의 각종 바이러스와 성인T-당뇨병 또는 HIV(인간면역 결핍바이러스)등의 레트로 바이러스의 감염을 방지하고 복제를 억제하며 또 박테리아, 곰광이등의 미생물의 성장 혹은 관상을 방지하며, 또한 아무런 부작용을 일으키지 않으면서 악성종양을 향상 및 치료하는 추출물을 얻을 수 있다.The present invention is an antiviral agent, an anticancer agent, and an antibacterial agent. According to the present invention, it prevents the infection and prevents the replication of various viruses such as influenza virus and hepatitis virus and retrovirus such as adult T-diabetic or HIV (human immunodeficiency virus). It also prevents the growth or coronation of microorganisms, such as bacteria and bears, and also obtains extracts that improve and treat malignant tumors without causing any side effects.

실시예Example

제조 예1Manufacturing Example 1

참깨를 정선수세하여 수분 15% 건조후 용기에 넣고 전자렌즌 용기에서 타지 않게 가열하여 압착추출하고 감자를 정선수세하여 압착추출액을 얻는다.Put sesame seeds in water and dry 15% of water, put them in a container and heat them in a microwave oven so that they do not burn.

참깨의 불포화지방산 추출, 감자의 알칼리 추출물을 1:1로 혼합하여 쥐 및 생쥐에 대해 실험을 행한바 사망률은 없고 동물의 이상행동이 관측되지 않으며 혈액의 생화학실험 및 조직의 병리실험에 이상값이 나타나지 않는다.Experiments were conducted on rats and mice with 1: 1 mixture of unsaturated fatty acid extracts and alkaline extracts of potatoes. No mortality was observed and no abnormal behavior was observed in the animals. Does not appear

본 발명은 항바이러스제, 항암제, 항박테리아제로서 본 발명에 의하면 인플루엔자바이러스로 타 바이러스 및 간염 바이러스 등의 각종 바이러스와 성인T-당뇨병 또는 HIV(인간면역 결핍바이러스)등의 레트로 바이러스의 감염을 방지하고 복제를 억제하며, 또 박테리아, 곰팡이등의 비생물의 성장 혹은 관장을 방지하며, 또한 아무런 부작용을 일으키지 않으면서 악성 종양을 향상 및 치료하는 추출물을 얻을 수 있다.The present invention is an antiviral agent, an anticancer agent, and an antibacterial agent. According to the present invention, it is possible to prevent infection of various viruses such as influenza virus, rotavirus and hepatitis virus, and retroviruses such as adult T-diabetes or HIV (human immunodeficiency virus). Extracts that inhibit replication, prevent the growth or enema of non-living organisms such as bacteria and fungi, and also improve and treat malignant tumors without causing any side effects can be obtained.

실험 예1Experimental Example 1

암에서 추출한 NUGC-4(1×10 세포/ml)를 20마리 쥐에게 피하주사한다. 다음날부터 실험관으로서, 이들 쥐들 중 10마리를 제조 예1에서 얻은 상기 추출물 100ml로 주사한다. 상기 추출물을 투여하지 않은 쥐대조군으로서 사용한다. 상기 추출물의 투여후 세포의 성장을 3주간 계산한다. 대조군에서 세포의 수는 현저하게 증가하는 반면 실험군에서 종양 세포의 증가는 현저하게 억제된다.NUGC-4 (1 × 10 cells / ml) extracted from cancer was injected subcutaneously into 20 rats. As a test tube from the next day, 10 of these mice were injected with 100 ml of the extract obtained in Preparation Example 1. The extract is used as a rat control group not administered. Cell growth is calculated for three weeks after administration of the extract. The number of cells in the control group is significantly increased while the increase in tumor cells in the experimental group is significantly suppressed.

실험 예2Experimental Example 2

암에서 추출한 NUGC-4를 20마리 쥐에게 피하주사한다. 다음날부터 실험군으로 이들 쥐들중 100마리를 제조 예1에서 얻은 상기 추출물 500mg/ml로 매일 주사한다. 상기 추출물을 투여하지 않은 쥐는 대조군으로서 사용한다. 상기 추출물의 투여후 세포의 성장을 한 달간 계산한다. 한달 후 대조군에서의 세포는 현저히 증가하여 취사 영역이 다소 존재하고 몇몇 동물은 죽어 있으나 실험관에서는 세포의 수는 현저히 억제되어 있어 죽은 동물은 없었다.NUGC-4 from cancer is injected subcutaneously into 20 rats. From the next day, 100 rats of these rats were injected daily with 500 mg / ml of the extract obtained in Preparation Example 1. Mice not administered the extract were used as controls. The growth of cells after administration of the extract is calculated for one month. After one month, the cells in the control group increased markedly, and there was some cooking area, and some animals died, but the number of cells in the test tube was significantly suppressed, and no animals died.

Claims (10)

본 발명은 유효성분으로서 참깨(Sasamum indicum L.) 불포화지방산과 감자(Patato) 알칼리 추출물로 이루어지는 항바이러스제The present invention is an antiviral agent consisting of sesame seeds (Sasamum indicum L.) unsaturated fatty acid and potato (Patato) alkali extract 제1항에 있어서 참깨 종실유 열매를 가열 압착추출된 불포화지방산과 감자 알칼리추출물 유효성분으로서 사용한 것을 특징으로하는 항바이러스제The antiviral agent according to claim 1, wherein the sesame seed oil fruit is used as an active ingredient of heat-extracted unsaturated fatty acid and potato alkali extract. 제1항 또는 제2항에 있어서 바이러스가 인간의 면역결핍성 바이러스(HIV)인 것을 특징으로 하는 항바이러스제The antiviral agent according to claim 1 or 2, wherein the virus is human immunodeficiency virus (HIV). 제1항 또는 제2항에 있어서 불포화지방산 성분은 팔미트산(Palmiticacid), 스테아르산(Stearic acid), 세사민(Sasamin) 0.4∼1.1%, 세사몰린(Sesamolin) 0.3∼0.6%, 세사몰(Sesamol) 알칼리추출물 성분은 비타민(Vitamins) B1(Thia-mine) 0.04mg B2(Ribo-favin) 0.04mg 니아신(Niacim) 0.4mg C(Asodrbic acid)99mg중의 하나인 것을 특징으로 하는 항바이러스제.The unsaturated fatty acid component according to claim 1 or 2 is palmitic acid, stearic acid, sasamin 0.4-1.1%, sesamolin 0.3-0.6%, sesamol ) Alkali extract component is one of vitamin (Vitamins) B1 (Thia-mine) 0.04mg B2 (Ribo-favin) 0.04mg Niacim 0.4mg C (Asodrbic acid) 99mg. 본 발명은 유효성분으로 참깨, 감자의 불포화지방산과 알칼리 추출물로 EC로 이루어지는 항암제.The present invention is an anticancer agent consisting of EC as sesame, unsaturated fatty acid and alkali extract of potato as an active ingredient. 제5항에 있어서 참깨, 감자를 가열 압착추출한 후 추출된 불포화지방산, 알칼리 추출물을 유효성분으로 사용하는 것을 특징으로 하는 항암제.[Claim 6] The anticancer agent according to claim 5, wherein the unsaturated fatty acid and the alkaline extract extracted after heat compression compression of sesame and potatoes are used as an active ingredient. 제5항 또는 제6항에 있어서 불포화지방산 성분은 팔미트산(Palmitic acid), 스태아르산(Stearic acid), 올레산(Oleic acid), 리놀레산(Linoleiei acid), 항산화성분 세사민(Sesamin) 0.4∼1.1%, 세사몰린(Sesamolin) 0.3∼0.6%, 세사몰(Sesamol) 감자성분은 비타민(Vitamins), B1(Thia-mime) 0.04mg, B2(Ribo-favin) 0.04mg, 니아신(Niacin) 0.4mg, C(Asodrbic acid) 99mg, 불포화지방산, 알칼리추출물로 이루어진 것을 특징으로하는 항암제The unsaturated fatty acid component according to claim 5 or 6 is palmitic acid, stearic acid, oleic acid, linoleic acid, antioxidant sesamin 0.4 to 1.1. %, Sesamolin 0.3 ~ 0.6%, Sesamol Potato Ingredients: Vitamin (Vitamins), B1 (Thia-mime) 0.04mg, B2 (Ribo-favin) 0.04mg, Niacin 0.4mg, C (Asodrbic acid) 99mg, unsaturated fatty acid, an anticancer agent characterized in that the alkali extract 본 발명은 참깨를 정선수세하여 수분 15% 건조후 전자젠즌 용기에 넣고 타지않게 가열 압착추출하고 감자를 정선수세하여 압착추출물 알칼리용액에 불포화지방산을 1:1로 혼합하여 항바이러스제를 제조하는 방법.The present invention is a method for producing an antiviral agent by mixing sesame seed with 15% moisture and drying it in an e-zen container, heating and compressing it without burning, and mixing the unsaturated fatty acid in the compressed extract alkaline solution in a 1: 1 manner. 제8항에 있어서 불포화지방산 성분은 팔미트산(Palmitic acid), 스테아르산(Stearic acid), 올레산(Oleic acid) 리놀레산(Linoleied acid), 항산화성분세사민(Sasamin) 0.4∼1.1%, 세사몰린(Sesamolin) 0.3∼0.6%, 세사몰(Sesamol) 감자성분은 비타민(Vitamins) B1(Thia-mine) 0.04mg B2(Ribo-favin) 0.04mg 니아신(Niacim) 0.4mg C(Asodrbic acid) 99mg중 비타민 EC로 이루어진 것을 특징으로 하는 항바이러스제의 제조방법.The unsaturated fatty acid component according to claim 8 is palmitic acid, stearic acid, oleic acid linoleic acid, antioxidant sasamin 0.4-1.1%, sesamolin ) 0.3 ~ 0.6%, Sesamol potato component is Vitamin EC in Vitamin (Vitamins) B1 (Thia-mine) 0.04mg B2 (Ribo-favin) 0.04mg Niacim 0.4mg C (Asodrbic acid) 99mg Method for producing an antiviral agent, characterized in that made. 본 발명은 참깨를 정선수세하여 수분 15% 건조후 전자렌즌 용기에 넣고 타지않게 가열 압착하고 감자를 정선수세하여 압착추출물을 1:1로 혼합하여 항암제를 제조하는 방법.The present invention is a method for producing an anticancer agent by mixing sesame extract with 1: 1 in a microwave oven, dried in a microwave oven, heat-pressed and put into a microwave oven in a sterilized manner.
KR1019990041858A 1999-09-29 1999-09-29 Antiviral agent and anticancer agent containing unsaturated fatty acid extract of sasamum indicum l. and alkaline extract of potato as active ingredients KR20010029185A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019990041858A KR20010029185A (en) 1999-09-29 1999-09-29 Antiviral agent and anticancer agent containing unsaturated fatty acid extract of sasamum indicum l. and alkaline extract of potato as active ingredients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990041858A KR20010029185A (en) 1999-09-29 1999-09-29 Antiviral agent and anticancer agent containing unsaturated fatty acid extract of sasamum indicum l. and alkaline extract of potato as active ingredients

Publications (1)

Publication Number Publication Date
KR20010029185A true KR20010029185A (en) 2001-04-06

Family

ID=19613290

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019990041858A KR20010029185A (en) 1999-09-29 1999-09-29 Antiviral agent and anticancer agent containing unsaturated fatty acid extract of sasamum indicum l. and alkaline extract of potato as active ingredients

Country Status (1)

Country Link
KR (1) KR20010029185A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007119378A1 (en) * 2006-03-15 2007-10-25 Suntory Limited Composition containing riboflavin and sesamins
WO2015076699A1 (en) * 2013-11-21 2015-05-28 Silezia Group Pte. Ltd Method of producing a substance with antimicrobial, antiviral, and immunostimulatory activities, a substance and a composition
US9609884B2 (en) 2007-03-15 2017-04-04 Suntory Holdings Limited Anti-fatigue agent
CN108088918A (en) * 2017-11-30 2018-05-29 吉林大学 The microwave assisted extraction methods and its condition optimizing method of unrighted acid in potato

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007119378A1 (en) * 2006-03-15 2007-10-25 Suntory Limited Composition containing riboflavin and sesamins
CN101410115B (en) * 2006-03-15 2012-01-04 三得利控股株式会社 Compositions containing riboflavin and sesamin-class compounds
AU2007237685B2 (en) * 2006-03-15 2012-08-09 Suntory Holdings Limited Compositions containing riboflavin and sesamin-class compounds
JP5430927B2 (en) * 2006-03-15 2014-03-05 サントリーホールディングス株式会社 Composition containing riboflavin and sesamin
KR101451438B1 (en) * 2006-03-15 2014-10-15 산토리 홀딩스 가부시키가이샤 Composition containing riboflavin and sesamins
US9895375B2 (en) 2006-03-15 2018-02-20 Suntory Holdings Limited Compositions containing riboflavin and sesamin-class compounds
US9609884B2 (en) 2007-03-15 2017-04-04 Suntory Holdings Limited Anti-fatigue agent
WO2015076699A1 (en) * 2013-11-21 2015-05-28 Silezia Group Pte. Ltd Method of producing a substance with antimicrobial, antiviral, and immunostimulatory activities, a substance and a composition
RU2563818C2 (en) * 2013-11-21 2015-09-20 Силезиа Груп Пте. Лтд. Method of obtaining substance, possessing antimicrobial, antiviral and immunostimulating activity, in particular, with respect to dendrite cells, substance, thereof obtained, and based on it pharmaceutical composition
US10342842B2 (en) 2013-11-21 2019-07-09 9541659 Canada Inc. Pharmaceutical compositions having antibacterial, antiviral, and other immunostimulatory activities
US10835565B2 (en) 2013-11-21 2020-11-17 9541659 Canada Inc. Pharmaceutical compositions having antibacterial, antiviral, and other immunostimulatory activities
CN108088918A (en) * 2017-11-30 2018-05-29 吉林大学 The microwave assisted extraction methods and its condition optimizing method of unrighted acid in potato

Similar Documents

Publication Publication Date Title
Namba Maitake D-fraction: healing and preventive potential for cancer
EP1300084B1 (en) Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves
KR100310979B1 (en) Natural pharmaceutical composition for prevention and treatment of hepatic disease.
KR20010029185A (en) Antiviral agent and anticancer agent containing unsaturated fatty acid extract of sasamum indicum l. and alkaline extract of potato as active ingredients
CN109568587A (en) Pharmaceutical combination preparations and radix aucklandiae, Radix Aucklandiae extract are preparing the application in chemotherapeutics Synergy and attenuation agent
CN102614228B (en) Application of pine needle fat-soluble extract to preparation of tumor treating medicament
KR20000073414A (en) Aaaaa
CN105943583B (en) Sweet wormwood herb and red yeast rice composition and application thereof
KR20010083663A (en) Antiviral and Anticancer Agents
CA2276276A1 (en) Cancer treatment drug
EP1207894B1 (en) Use of a synergistic composition for the manufacture of a medicament for the treatment of liver associated ailments
KR102052081B1 (en) The composition for preventing and treating hepatitis B
CN105246472B (en) Composition containing ornithine and/or L-aminobutanedioic acid and its application
JPH06199696A (en) Carcinostatic anticancer agent
WO2007069204A2 (en) Antiviral, virucid and immunomodulant officinal plant-based composition and related method for the treatment of viral diseases, in particular of hiv infection.
KR20010077474A (en) Antiviral and Anticancer Agents
KR20120027887A (en) Antiviral and Anticancer Agents
US20070224214A1 (en) Composition Exerting Physiological Activity Via Biological Immune Mechanism
KR20010074416A (en) Antiviral and Anticancer Agents
Ayunda et al. Scholars Academic Journal of Pharmacy
KR20010083664A (en) Antiviral and Anticancer Agents
WO2022159055A1 (en) An olive leaf extract and production method thereof
KR20010089923A (en) Antiviral and Anticancer Agents
KR20010083662A (en) Antiviral and Anticancer Agents
KR20010077472A (en) Antiviral and Anticancer Agents

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid